- Home
- SNES vs PBM Comparison
SNES vs PBM Comparison
Compare SNES & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- PBM
- Stock Information
- Founded
- SNES 2004
- PBM 1994
- Country
- SNES United States
- PBM Canada
- Employees
- SNES N/A
- PBM N/A
- Industry
- SNES Agricultural Chemicals
- PBM
- Sector
- SNES Industrials
- PBM
- Exchange
- SNES Nasdaq
- PBM NYSE
- Market Cap
- SNES 2.3M
- PBM 2.8M
- IPO Year
- SNES 2016
- PBM N/A
- Fundamental
- Price
- SNES $3.16
- PBM $1.53
- Analyst Decision
- SNES Strong Buy
- PBM
- Analyst Count
- SNES 1
- PBM 0
- Target Price
- SNES $10.00
- PBM N/A
- AVG Volume (30 Days)
- SNES 311.7K
- PBM 2.2M
- Earning Date
- SNES 11-12-2024
- PBM 02-02-2025
- Dividend Yield
- SNES N/A
- PBM N/A
- EPS Growth
- SNES N/A
- PBM N/A
- EPS
- SNES N/A
- PBM N/A
- Revenue
- SNES $1,651,000.00
- PBM N/A
- Revenue This Year
- SNES $91.45
- PBM N/A
- Revenue Next Year
- SNES $101.31
- PBM N/A
- P/E Ratio
- SNES N/A
- PBM N/A
- Revenue Growth
- SNES 38.16
- PBM N/A
- 52 Week Low
- SNES $1.90
- PBM $1.51
- 52 Week High
- SNES $21.40
- PBM $945.15
- Technical
- Relative Strength Index (RSI)
- SNES 56.47
- PBM 20.19
- Support Level
- SNES $2.32
- PBM $1.85
- Resistance Level
- SNES $5.00
- PBM $2.11
- Average True Range (ATR)
- SNES 0.52
- PBM 0.55
- MACD
- SNES 0.13
- PBM 0.07
- Stochastic Oscillator
- SNES 35.66
- PBM 0.80
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.